Is CJC-1295 legit? A calm reading of the research and the regulatory record.

The short version

CJC-1295 is a synthetic peptide that mimics the hormone your brain uses to tell your pituitary to release growth hormone (GH). Two things make it unusual: it resists the enzymes that normally destroy such hormones within minutes, and it binds to a common blood protein called albumin, giving it a half-life of roughly six to eight days. A single small injection can keep GH and its downstream signal, IGF-1, elevated for over a week.

Two placebo-controlled trials in healthy adults confirm these effects in humans ^[1][3]. Research interest centers on sleep quality, body composition, and recovery — areas communities report noticing effects page. The compound is not FDA-approved, was not recommended for compounding by the 2024 advisory committee, and is prohibited in sport year-round by WADA. There are no long-term human safety studies. It is a research chemical, handled as such.

What is CJC-1295?

CJC-1295 is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that signals the anterior pituitary gland to produce and secrete growth hormone (GH). It was developed by ConjuChem Biotechnologies in Montreal and identified in a 2005 study that characterized it as a long-lasting GRF analog ^[6].

Native GHRH has a plasma half-life of only 7–10 minutes, because an enzyme called dipeptidyl peptidase-IV (DPP-IV) rapidly cleaves the peptide's N-terminal amino acids after it enters circulation. CJC-1295 addresses this in two distinct ways. First, four amino acid substitutions (including a D-Ala at position 2) make it resistant to DPP-IV cleavage. Second — and more unusual — a reactive maleimide group attached to the peptide's C-terminus spontaneously forms a covalent thioether bond with the Cys34 residue of circulating serum albumin shortly after subcutaneous injection. This 'Drug Affinity Complex' (DAC) mechanism creates a ~67 kDa macromolecular conjugate that is too large for renal filtration and is protected from further proteolysis ^[12]. The result is a half-life of 5.8–8.1 days in humans ^[3].

A closely related compound, Modified GRF 1-29 (sometimes labeled 'CJC-1295 without DAC'), shares the same four amino acid substitutions but lacks the albumin-binding DAC moiety. Its half-life is approximately 30 minutes — substantially shorter than CJC-1295 DAC but meaningfully longer than native GHRH. The two peptides are structurally related but pharmacokinetically distinct, and this distinction affects how they are used in research protocols ^[13].

CJC-1295 was developed with therapeutic applications in mind, including growth hormone deficiency and lipodystrophy associated with HIV. Two placebo-controlled Phase 1/2 trials in healthy adults were conducted; a Phase 2 trial in HIV lipodystrophy (NCT00267527) was discontinued in 2006 after one participant death, which investigators attributed to pre-existing coronary disease rather than the study drug. ConjuChem nonetheless halted commercial development. No FDA-approved indication exists for CJC-1295.

What the published research shows

The primary human evidence for CJC-1295 comes from a 2006 randomized, double-blind, placebo-controlled trial in 65 healthy adults aged 21–61, published in the Journal of Clinical Endocrinology & Metabolism by Teichman and colleagues ^[1][2][3]. In that trial, a single subcutaneous injection at doses ranging from 30 to 120 μg/kg produced dose-dependent increases in mean plasma GH concentrations lasting six days or more. Mean plasma IGF-1 (the liver-derived downstream marker of GH activity) rose 1.5- to 3-fold and remained elevated for 9–11 days. The best tolerability was observed at 30–60 μg/kg; no serious adverse events were reported in this Phase 1/2 study.

Multiple-dose administration at 30–60 μg/kg once or twice weekly maintained mean IGF-1 levels above baseline for up to 28 days post-final dose in the same trial cohort ^[2]. Pulsatile GH secretion — the normal physiological pattern of GH release occurring in 8–12 daily bursts — was preserved throughout, unlike exogenous GH therapy, which suppresses the body's own GH pulse pattern.

A 2009 proteomic study in 11 healthy men (aged 20–34) found that a single 60–90 μg/kg dose produced measurable changes in five serum protein fractions, including significant changes in apolipoprotein A1 and transthyretin ^[8]. This adds to the evidence that CJC-1295's GH/IGF-1 axis activation has downstream effects beyond IGF-1 alone.

In animal studies, once-daily administration at 2 μg/day normalized body weight, body length, and bone mineral density in GHRH-knockout mice over five weeks ^[4]. Somatotroph cell proliferation in the anterior pituitary was confirmed by immunohistochemistry ^[5], and a 4-fold increase in GH area under the curve relative to native GRF(1-29) was documented in Sprague Dawley rats ^[6].

The research base also includes anti-doping analytics. CJC-1295 was identified by liquid chromatography-high resolution mass spectrometry in an illicit pharmaceutical preparation submitted by Norwegian anti-doping authorities ^[9], and subsequent studies developed validated detection methods for equine plasma using immuno-PCR (0.8 pg/mL sensitivity) ^[10] and LC-MS/MS (180 pg/mL) ^[11].

More recently, a 2024 review of GHRH analog development documented that the pharmacological class CJC-1295 belongs to has been studied for angiogenesis in critical limb ischemia, wound healing via fibroblast proliferation, and cardiac repair post-infarction in rodent models ^[20]. A 2026 gerontology review noted that CJC-1295 combined with ipamorelin improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss ^[18].

The regulatory picture

The regulatory status of CJC-1295 is unresolved, and understanding what the record actually shows matters.

CJC-1295 is not an FDA-approved drug. It does not hold an approved New Drug Application and no active Investigational New Drug application for commercial development is on file as of mid-2026. It is not a scheduled controlled substance under the Controlled Substances Act and has no DEA scheduling.

For licensed compounding pharmacies operating under 21 U.S.C. § 503A, the picture became clearer in late 2024. CJC-1295 was initially placed on the FDA's interim 503A Category 2 bulks list (substances under evaluation with identified safety concerns), then removed in September 2024 after nominators withdrew their nominations ^[15]. In December 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed CJC-1295 and voted against its inclusion on the 503A Bulks Regulation. The committee cited cardiovascular adverse event reports in the clinical record, immunogenicity concerns related to the albumin-conjugate structure, and insufficient compounding-specific safety data ^[14]. As of mid-2026, no Federal Register notice has been published authorizing compounding. CJC-1295 compounding by 503A pharmacies is not authorized under current FDA guidance.

For athletes subject to anti-doping rules, CJC-1295 is prohibited by the World Anti-Doping Agency under Section S2.2.4 (Growth Hormone Releasing Factors) of the WADA Prohibited List, year-round — both in-competition and out-of-competition ^[16]. Strict liability applies, meaning athletes are responsible for prohibited substances in their systems regardless of intent. U.S. Department of Defense military anti-doping protocols incorporate WADA standards.

What this site is

CJC-1295 Legit is an independent editorial project. It summarizes the peer-reviewed research literature and the public regulatory record on CJC-1295 — the published studies, the FDA proceedings, the WADA prohibition, and the open questions. It does not provide medical advice or research guidance.

The name 'Legit' reflects the editorial frame: a calm, plain-language reading of what the record actually says, without agenda. The compound has a real mechanism, real peer-reviewed data, and a real regulatory record — and all three deserve accurate representation.